Increased glutathione and mitogen-activated protein kinase phosphorylation are involved in the induction of doxorubicin resistance in hepatocellular carcinoma cells

Hepatology Research

Volumn 43, Issue 3, 2013, Pages 289-299

  Ye, Cai Guo ^a,b   Yeung, John Hok Keung ^a   Huang, Guo Liang ^a   Cui, Ping ^a   Wang, Jian ^a   Zou, Yin ^a   Zhang, Xiang Ning ^a   He, Zhi Wei ^a   Cho, Chi Hin ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Glutathione; Mitogen activated protein kinase; Multidrug resistant associated protein 1; P glycoprotein; Sorafenib

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOXORUBICIN; GLUTATHIONE PEROXIDASE; I KAPPA B ALPHA; MITOGEN ACTIVATED PROTEIN KINASE P38; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; REACTIVE OXYGEN METABOLITE; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE S PHASE; CELL STRAIN HEPG2; CELL VIABILITY; CONFOCAL MICROSCOPY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84874320076     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01067.x     Document Type: Article

References (41)

1. Bradley G, Sharma R, Rajalakshmi S etal. P-glycoprotein expression during tumor progression in the rat liver. Cancer Res 1992; 52: 5154-61.
2. Michaelis M, Rothweiler F, Klassert D etal. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res 2009; 69: 416-21.
3. Ye CG, Wu WK, Yeung JH etal. Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression. Cancer Lett 2011; 304: 90-6.
4. Li G, Chen X, Wang Q etal. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance. J Huazhong Univ Sci Technolog Med Sci 2007; 27: 173-5.
5. Mannermaa E, Vellonen KS, Ryhanen T etal. Efflux protein expression in human retinal pigment epithelium cell lines. Pharm Res 2009; 26: 1785-91.
6. Swerts K, De Moerloose B, Dhooge C etal. Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. Eur J Cancer 2006; 42: 295-309.
7. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005; 204: 216-37.
8. Barr RK, Bogoyevitch MA. The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). Int J Biochem Cell Biol 2001; 33: 1047-63.
9. Osborn MT, Chambers TC. Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J Biolf Chem 1996; 271: 30950-5.
10. Kolbus A, Herr I, Schreiber M etal. c-Jun-dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents. Mol Cell Biol 2000; 20: 575-82.
11. Brozovic A, Fritz G, Christmann M etal. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer 2004; 112: 974-85.
12. Shareef MM, Brown B, Shajahan S etal. Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-kappaB and NF-Y activation in oral carcinoma cells. Mol Cancer Res 2008; 6: 89-98.
13. Kuo MT, Liu Z, Wei Y etal. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene 2002; 21: 1945-54.
14. Choi BH, Kim CG, Lim Y etal. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett 2008; 259: 111-18.
15. Morales MC, Perez-Yarza G, Nieto-Rementeria N etal. Intracellular glutathione levels determine cell sensitivity to apoptosis induced by the antineoplasic agent N-(4-hydroxyphenyl) retinamide. Anticancer Res 2005; 25: 1945-51.
16. Maeda H, Hori S, Ohizumi H etal. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ 2004; 11: 737-46.
17. Anuszewska EL, Gruber BM, Koziorowska JH. Studies on adaptation to adriamycin in cells pretreated with hydrogen peroxide. Biochem Pharmacol 1997; 54: 597-603.
18. Huang ZZ, Chen C, Zeng Z etal. Mechanism and significance of increased glutathione level in human hepatocellular carcinoma and liver regeneration. FASEB J 2001; 15: 19-21.
19. Ghibelli L, Fanelli C, Rotilio G etal. Rescue of cells from apoptosis by inhibition of active GSH extrusion. FASEB J 1998; 12: 479-86.
20. Santamaria A, Vazquez-Roman B, La Cruz VP etal. Selenium reduces the proapoptotic signaling associated to NF-kappaB pathway and stimulates glutathione peroxidase activity during excitotoxic damage produced by quinolinate in rat corpus striatum. Synapse 2005; 58: 258-66.
21. Ki MR, Goo MJ, Park JK etal. Helicobacter pylori accelerates hepatic fibrosis by sensitizing transforming growth factor-beta1-induced inflammatory signaling. Lab Invest 2010; 90: 1507-16.
22. Korotkina RN, Matskevich GN, Devlikanova A etal. Activity of glutathione-metabolizing and antioxidant enzymes in malignant and benign tumors of human lungs. Bull Exp Biol Med 2002; 133: 606-8.
23. Tsang WP, Kwok TT. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene 2007; 26: 4877-81.
24. Boldyrev AA. Discrimination between apoptosis and necrosis of neurons under oxidative stress. Biochemistry (Mosc) 2000; 65: 834-42.
25. Zegura B, Lah TT, Filipic M. Alteration of intracellular GSH levels and its role in microcystin-LR-induced DNA damage in human hepatoma HepG2 cells. Mutat Res 2006; 611: 25-33.
26. Turk D, Szakacs G. Relevance of multidrug resistance in the age of targeted therapy. Curr Opin Drug Discov Devel 2009; 12: 246-52.
27. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
28. Suzuki T, Yokozaki H, Kuniyasu H etal. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer 2000; 88: 992-7.
29. Simizu S, Takada M, Umezawa K etal. Requirement of caspase-3(-like) protease-mediated hydrogen peroxide production for apoptosis induced by various anticancer drugs. J Biol Chem 1998; 273: 26900-7.
30. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 2010; 48: 749-62.
31. Mueller CF, Widder JD, McNally JS etal. The role of the multidrug resistance protein-1 in modulation of endothelial cell oxidative stress. Circ Res 2005; 97: 637-44.
32. Das PK, Bagchi SN. Role of bacterioferritin comigratory protein and glutathione peroxidase-reductase system in promoting bentazone tolerance in a mutant of Synechococcus elongatus PCC7942. Protoplasma 2011; 249: 65-74.
33. Swiderska-Kolacz G, Klusek J, Kolataj A. The effect of melatonin on glutathione and glutathione transferase and glutathione peroxidase activities in the mouse liver and kidney in vivo. Neuro Endocrinol Lett 2006; 27: 365-8.
34. Aronov AM, Baker C, Bemis GW etal. Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. J Med Chem 2007; 50: 1280-7.
35. Bennett BL, Sasaki DT, Murray BW etal. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 2001; 98: 13681-6.
36. Barancik M, Bohacova V, Kvackajova J etal. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci 2001; 14: 29-36.
37. Tan Y, Rouse J, Zhang A etal. FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J 1996; 15: 4629-42.
38. Huang Y, Wang Y, Li Y etal. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2. J Cancer Res Clin Oncol 2011; 137: 829-37.
39. Shiota M, Eto M, Yokomizo A etal. Sensitivity of doxorubicin-resistant cells to sorafenib: possible role for inhibition of eukaryotic initiation factor-2alpha phosphorylation. Int J Oncol 2010; 37: 509-17.
40. Shibayama Y, Nakano K, Maeda H etal. Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull 2011; 34: 433-5.
41. Gnoth MJ, Sandmann S, Engel K etal. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein. Drug Metab Dispos 2010; 38: 1341-6.